Denali Therapeutics Inc. (NASDAQ:DNLI) Expected to Announce Earnings of -$0.56 Per Share

Equities analysts predict that Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) will post earnings of ($0.56) per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Denali Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.87). Denali Therapeutics posted earnings per share of ($0.50) during the same quarter last year, which suggests a negative year over year growth rate of 12%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Denali Therapeutics will report full year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($3.01) to ($2.32). For the next year, analysts expect that the business will report earnings of ($2.57) per share, with EPS estimates ranging from ($3.30) to ($0.90). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLIGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Denali Therapeutics had a negative net margin of 344.79% and a negative return on equity of 28.13%. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $33.32 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The business’s revenue was up 432.9% compared to the same quarter last year.

Several equities analysts have commented on DNLI shares. Wedbush decreased their target price on shares of Denali Therapeutics from $62.00 to $48.00 in a report on Friday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating on the stock in a research note on Monday, March 7th. Finally, TheStreet cut Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Wednesday, March 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $81.67.

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the firm’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $33.83, for a total transaction of $676,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 17.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. HM Payson & Co. bought a new stake in Denali Therapeutics during the 4th quarter worth approximately $26,000. Lindbrook Capital LLC acquired a new position in shares of Denali Therapeutics during the fourth quarter worth $27,000. Dark Forest Capital Management LP grew its stake in shares of Denali Therapeutics by 19,733.3% in the third quarter. Dark Forest Capital Management LP now owns 595 shares of the company’s stock worth $30,000 after purchasing an additional 592 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in Denali Therapeutics by 125.3% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 811 shares of the company’s stock valued at $36,000 after purchasing an additional 451 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Denali Therapeutics during the 3rd quarter worth $45,000. Institutional investors and hedge funds own 72.32% of the company’s stock.

DNLI stock traded up $1.03 during midday trading on Friday, reaching $22.86. The company had a trading volume of 1,006,021 shares, compared to its average volume of 546,280. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of -9.77 and a beta of 1.90. Denali Therapeutics has a 1-year low of $20.24 and a 1-year high of $79.70. The stock has a 50 day moving average price of $29.38 and a 200-day moving average price of $37.21.

About Denali Therapeutics (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Recommended Stories

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.